-
公开(公告)号：US10517861B2
公开(公告)日：2019-12-31
申请号：US14890207
申请日：2014-05-12
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yasuhiro Funahashi , Tadashi Kadowaki , Pallavi Sachdev
IPC: A61K31/47 , G01N33/574
Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
-
公开(公告)号：US20180136216A1
公开(公告)日：2018-05-17
申请号：US15573197
申请日：2016-05-27
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Yasuhiro Funahashi , Tadashi Kadowaki
IPC: G01N33/574
CPC classification number: G01N33/57438 , G01N2800/52
Abstract: Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is in need of a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.
-
3.发明申请公开(公告)号：US20180209980A1
公开(公告)日：2018-07-26
申请号：US15934242
申请日：2018-03-23
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yasuhiro Funahashi , Tadashi Kadowaki , Junji Matsui , Jason S. Simon , Lucy Xu
IPC: G01N33/574 , C12Q1/6886 , A61K31/47
CPC classification number: G01N33/57407 , A61K31/47 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N33/57438
Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
-
Patent Agency Ranking
公开(公告)号：US20140148483A1
公开(公告)日：2014-05-29
申请号：US14117276
申请日：2012-05-16
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Taro Semba , Yusuke Narita , Yukinori Minoshima , Atsumi Yamaguchi , Yusuke Adachi , Kazuhiko Yamada , Junji Matsui , Tadashi Kadowaki , Kentaro Takahashi , Yasuhiro Funahashi
CPC classification number: C12Q1/6886 , A61K31/4025 , A61K31/404 , A61K31/47 , A61K31/517 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/574 , G01N33/5748 , G01N33/57488 , G01N33/57496 , G01N2333/515 , G01N2333/82 , G01N2333/916 , G01N2800/52
Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
Abstract translation: 本发明的目的是提供一种用于预测患有肿瘤的受试者中血管生成抑制剂的有效性的方法。 提供了一种方法，其包括测试来自受试者的肿瘤组织样品中是否存在B-Raf和PTEN的突变或丧失的表达的存在或不存在的步骤。 通过使用B-Raf和PTEN的表达的存在或不存在或突变或丧失作为指标，该方法能够预测血管生成抑制剂的抗肿瘤效力，而不向受试者施用血管生成抑制剂。
-
5.发明申请BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS 审中-公开生物标志物预测和评估内膜癌患者对列萘醌化合物的反应公开(公告)号：US20160089366A1
公开(公告)日：2016-03-31
申请号：US14890207
申请日：2014-05-12
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Yasuhiro Funahashi , Tadashi Kadowaki , Pallavi Sachdev
IPC: A61K31/47 , G01N33/574
CPC classification number: A61K31/47 , G01N33/57442 , G01N2333/475 , G01N2333/515 , G01N2800/52
Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
Abstract translation: 提供了生物标志物，其预测具有子宫内膜癌的受试者是否会对包含联苯卡因或其药学上可接受的盐（例如甲磺酸伦伐他汀）的治疗作出反应。 本文描述的生物标志物，组合物和方法可用于选择具有怀疑具有或有发展子宫内膜癌风险的受试者的适当治疗方式。
-
公开(公告)号：US20230212679A1
公开(公告)日：2023-07-06
申请号：US17692698
申请日：2022-03-11
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Taro Semba , Yusuke Narita , Yukinori Minoshima , Atsumi Yamaguchi , Yusuke Adachi , Kazuhiko Yamada , Junji Matsui , Tadashi Kadowaki , Kentaro Takahashi , Yasuhiro Funahashi
IPC: C12Q1/6886 , A61K31/47 , G01N33/574 , A61K31/517 , A61K31/404 , A61K31/4025
CPC classification number: C12Q1/6886 , A61K31/47 , A61K31/404 , A61K31/517 , A61K31/4025 , G01N33/574 , G01N33/5748 , G01N33/57488 , G01N33/57496 , C12Q2600/16 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , G01N2333/82 , G01N2333/515 , G01N2333/916 , G01N2800/52
Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
-
公开(公告)号：US11598776B2
公开(公告)日：2023-03-07
申请号：US15934242
申请日：2018-03-23
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yasuhiro Funahashi , Tadashi Kadowaki , Junji Matsui , Jason S. Simon , Lucy Xu
IPC: G01N33/53 , G01N33/574 , C12Q1/6886 , A61K31/47
Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
-
公开(公告)号：US20170191137A1
公开(公告)日：2017-07-06
申请号：US15460629
申请日：2017-03-16
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Taro Semba , Yusuke Narita , Yukinori Minoshima , Atsumi Yamaguchi , Yusuke Adachi , Kazuhiko Yamada , Junji Matsui , Tadashi Kadowaki , Kentaro Takahashi , Yasuhiro Funahashi
IPC: C12Q1/68 , G01N33/574 , A61K31/47
CPC classification number: C12Q1/6886 , A61K31/4025 , A61K31/404 , A61K31/47 , A61K31/517 , C12Q2600/106 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16 , G01N33/574 , G01N33/5748 , G01N33/57488 , G01N33/57496 , G01N2333/515 , G01N2333/82 , G01N2333/916 , G01N2800/52
Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.029 seconds)
